Sama kawa nie oddziałuje na metabolizm w żaden sposób




Int J Obes Relat Metab Disord. 1992 Apr;16(4):269-77.

The effect and safety of an ephedrine/caffeine compound compared to
ephedrine, caffeine and placebo in obese subjects on an energy restricted
diet. A double blind trial.

The sympathomimetic agent ephedrine has potent thermogenic and anti-obesity
properties in rodents. The effect is markedly enhanced by caffeine, while
caffeine given alone has no effect. This study was undertaken to find out if
a similar weight reducing synergism between ephedrine and caffeine is
present in obese patients. In a randomized, placebo-controlled, double blind
study, 180 obese patients were treated by diet (4.2 MJ/day) and either an
ephedrine/caffeine combination (20mg/200mg), ephedrine (20 mg), caffeine
(200 mg) or placebo three times a day for 24 weeks. Withdrawals were
distributed equally in the four groups, and 141 patients completed the
trial. Mean weight losses was significantly greater with the combination
than with placebo from week 8 to week 24 (ephedrine/caffeine, 16.6 +/- 6.8
kg vs. placebo, 13.2 +/- 6.6 kg (mean +/- s.d.), P = 0.0015). Weight loss in
both the ephedrine and the caffeine groups was similar to that of the
placebo group. Side effects (tremor, insomnia and dizziness) were transient
and after eight weeks of treatment they had reached placebo levels. Systolic
and diastolic blood pressure fell similarly in all four groups. We conclude,
that in analogy with animal studies, the ephedrine/caffeine combination is
effective, while caffeine and ephedrine separately are ineffective for the
treatment of human obesity.

Za to to jest ciekawe:)

Schizophr Res. 2006 Jun 17; [Epub ahead of print]
Fewer but heavier caffeine consumers in schizophrenia: A case-control study.

According to the literature, there is an association between schizophrenia
and caffeine consumption, but it is not clear whether schizophrenia is
associated with either higher prevalence of daily caffeine intake or the
amount consumed. In this study we compared our previously published
schizophrenia patients (n=250) with a control sample (n=290) after
controlling for demographic variables and tobacco and alcohol consumption.
Current caffeine intake was less frequent in schizophrenia patients (59%,
147/250) than in controls (70%, 204/290). In the multivariate analyses,
caffeine intake was less frequent at an older age and in schizophrenia
patients, and more frequent in smokers and alcohol users. Among caffeine
consumers, heavy caffeine intake (>/=200 mg/day) was significantly
associated with schizophrenia (64%, 94/147 in schizophrenia versus 36%,
73/204 in controls), as well as older age and smoking. Daily amount of
caffeine intake and smoked cigarettes correlated significantly in the
schizophrenia group but not in the control group; the correlation of
caffeine intake with nicotine dependence was low and non-significant in both
groups. The association between current smoking and heavy caffeine intake
may be partly explained by a pharmacokinetic effect: tobacco smoke compounds
induce caffeine metabolism by the cytochrome P450 1A2. Although
schizophrenia by itself may be associated with heavy caffeine intake in
caffeine users, part of this association was explained by the association
between schizophrenia and smoking. The relationship between caffeine and
alcohol intake appeared to be more complex; alcohol and caffeine use were
significantly associated, but within caffeine users alcohol was associated
with less frequent heavy caffeine consumption among smokers. In future
studies, the measurement of plasma caffeine levels will help both to better
define heavy caffeine intake and to control for smoking pharmacokinetic
effects.